Brief: Sirnaomics Announces Successful Completion Of Cohort 1 From Phase I Clinical Study Of Galnac-Based Rnai Therapeutic Stp122g For Anticoagulant Treatment
05/12/2023 17:27
Sirnaomics Ltd 2257.HK :
* SIRNAOMICS ANNOUNCES SUCCESSFUL COMPLETION OF COHORT 1
FROM
PHASE I CLINICAL STUDY OF GALNAC-BASED RNAI THERAPEUTIC STP122G
FOR ANTICOAGULANT TREATMENT
* SIRNAOMICS LTD - LOOK FORWARD TO CONTINUING TO EXAMINE
EFFICACY
OF STP122G INTO 2024
Source text for Eikon: ID:nPn1WWCRWa
Further company coverage: 2257.HK
Recent news on Sirnaomics
See all newsBrief: Sirnaomics To Issue 2.4 Million New Shares At Hk$4.69 Each Under General Mandate
Brief: Sirnaomics Says Chairman Purchases 38,000 Shares At Average Price Hk$5.93 Per Share
Brief: Sirnaomics Ltd To Issue 17.4 Million Subscription Shares
Brief: Sirnaomics Says Poon Hung Fai Appointed As Chairman
Brief: Sirnaomics Posts FY Net Income USD -50.2 Million